US2004052863A1PendingUtilityA1

Nutritional supplement to treat macular degeneration

46
Priority: Mar 23, 2001Filed: Aug 15, 2003Published: Mar 18, 2004
Est. expiryMar 23, 2021(expired)· nominal 20-yr term from priority
Inventors:Stephen BartelsCara BaustianGeorge BunceLeon EllenbogenFrederick FerrisJin KinoshitaJames SmithDavid Souerwine
A61P 27/12A61P 3/02A61P 27/02A61K 33/34A61K 31/355A23L 5/44A61K 33/30A61K 31/375A23V 2002/00A61K 31/07A23L 33/15A23L 33/16A23L 33/155A23L 33/105
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A composition comprising: 
 approximately 7 to 10 times the RDA of vitamin C;    approximately 13 to 18 times the RDA of vitamin E;    approximately 6 to 10 times the RDA of vitamin A in the form of beta-carotene;    approximately 4 to 7 times the RDA of zinc; and    approximately the RDA of copper.    
     
     
         2 . A retinal health strengthening composition comprising: 
 approximately 7 to 10 times the RDA of vitamin C;    approximately 13 to 18 times the RDA of vitamin E;    approximately 6 to 10 times the RDA of vitamin A in the form of beta-carotene;    approximately 4 to 7 times the RDA of zinc; and    approximately the RDA of copper.    
     
     
         3 . A nutritional or dietary supplement composition to safely and effectively prevent, stabilize, reverse and/or treat visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the formation of cataracts and the progression of age-related macular degeneration comprising: 
 approximately 7 to 10 times the RDA of vitamin C;    approximately 13 to 18 times the RDA of vitamin E;    approximately 6 to 10 times the RDA of vitamin A in the form of beta-carotene;    approximately 4 to 7 times the RDA of zinc; and    approximately the RDA of copper.    
     
     
         4 . A method of safely and effectively preventing, stabilizing, reversing and/or treating visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the development of cataracts and the progression of age-related macular degeneration comprising: 
 administering a daily dosage of not less than approximately 420 mg and not more than approximately 600 mg vitamin C, not less than approximately 400 IU and not more than approximately 540 IU vitamin E, not less than approximately 17.2 mg and not more than approximately 28 mg beta-carotene, not less than approximately 60 mg and not more than approximately 100 mg zinc and not less than approximately 1.6 mg and not more than approximately 2.4 mg copper.    
     
     
         5 . A method of manufacturing a nutritional supplement composition that is safe and effective in preventing, stabilizing, reversing and/or treating visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the development of cataracts and the progression of age-related macular degeneration comprising: 
 blending not less than approximately 420 mg and not more than approximately 600 mg vitamin C, not less than approximately 400 IU and not more than approximately 540 IU vitamin E, not less than approximately 17.2 mg and not more than approximately 28 mg beta-carotene, not less than approximately 60 mg and not more than approximately 100 mg zinc and not less than approximately 1.6 mg and not more than approximately 2.4 mg copper into a suitable dosage form.    
     
     
         6 . A method of manufacturing a composition comprising: 
 blending not less than approximately 420 mg and not more than approximately 600 mg vitamin C, not less than approximately 400 IU and not more than approximately 540 IU vitamin E, not less than approximately 17.2 mg and not more than approximately 28 mg beta-carotene, not less than approximately 60 mg and not more than approximately 100 mg zinc and not less than approximately 1.6 mg and not more than approximately 2.4 mg copper into a suitable dosage form.    
     
     
         7 . The composition of  claim 1 ,  2  or  3  wherein said composition comprises not less than approximately 450 mg vitamin C, not less than approximately 400 IU vitamin E, not less than approximately 17.2 mg beta-carotene, not less than approximately 68 mg zinc and not less than approximately 1.6 mg copper.  
     
     
         8 . The composition of  claim 1 ,  2  or  3  wherein said vitamin C is provided in the form of ascorbic acid.  
     
     
         9 . The composition of  claim 1 ,  2  or  3  wherein said vitamin E is provided in the form of dl-alpha tocopheryl acetate.  
     
     
         10 . The composition of  claim 1 ,  2  or  3  wherein said beta-carotene is substituted or supplemented with lutein, zeaxanthine or a raw material combination thereof.  
     
     
         11 . The composition of  claim 1 ,  2  or  3  wherein said composition is supplemented with alpha-lipoic acid, phenolic compounds, anthocyanosides or a combination thereof.  
     
     
         12 . The composition of  claim 1 ,  2  or  3  wherein said zinc is provided in the form of zinc oxide, zinc gluconate or a combination thereof.  
     
     
         13 . The composition of  claim 1 ,  2  or  3  wherein said copper is provided in the form of cupric oxide, copper gluconate or a combination thereof.  
     
     
         14 . The method of  claim 5  or  6  wherein said blend provides not less than approximately 450 mg vitamin C, not less than approximately 400 IU vitamin E, not less than approximately 17.2 mg beta-carotene, not less than approximately 68 mg zinc, and not less than approximately 1.6 mg copper, up until an expiration date of said dosage form produced from said blend.  
     
     
         15 . The method of  claim 4 ,  5  or  6  wherein said vitamin C is provided in the form of ascorbic acid.  
     
     
         16 . The method of  claim 4 ,  5  or  6  wherein said vitamin E is provided in the form of dl-alpha tocopheryl acetate.  
     
     
         17 . The method of  claim 4 ,  5  or  6  wherein said beta-carotene is substituted or supplemented with lutein, zeaxanthine, or a raw material combination thereof.  
     
     
         18 . The method of  claim 4 ,  5  or  6  wherein said composition is supplemented with alpha-lipoic acid, phenolic compounds, anthocyanosides or a combination thereof.  
     
     
         19 . The method of  claim 4 ,  5  or  6  wherein said zinc is provided in the form of zinc oxide, zinc gluconate or a combination thereof.  
     
     
         20 . The method of  claim 4 ,  5  or  6  wherein said copper is provided in the form of copper oxide, copper gluconate or a combination thereof.  
     
     
         21 . The composition of  claim 1 ,  2  or  3  wherein said composition is formed into one or more tablets for daily oral ingestion by a human or other mammal.  
     
     
         22 . The composition of  claim 1 ,  2  or  3  wherein said composition is formed into four tablets for oral ingestion by a patient of two tablets twice daily.  
     
     
         23 . The method of  claim 4  wherein said daily dosage is administered orally in the form of one or more tablets taken daily.  
     
     
         24 . The method of  claim 4  wherein said daily dosage is administered orally in the form of two tablets taken twice daily.  
     
     
         25 . The method of  claim 5  or  6  wherein said composition is compressed in the form of two tablets taken twice daily.

Join the waitlist — get patent alerts

Track US2004052863A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.